Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Deferred Taxes (2021 - 2024)

Prime Medicine (PRME) has disclosed Deferred Taxes for 4 consecutive years, with -$134000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Deferred Taxes fell 532.26% year-over-year to -$134000.0, compared with a TTM value of -$134000.0 through Mar 2025, down 335.09%, and an annual FY2023 reading of -$279000.0, up 71.06% over the prior year.
  • Deferred Taxes was -$134000.0 for Q2 2024 at Prime Medicine, down from $134000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $1.2 million in Q4 2021 and bottomed at -$532000.0 in Q1 2022.
  • Average Deferred Taxes over 4 years is $0.0, with a median of -$121000.0 recorded in 2023.
  • Peak annual rise in Deferred Taxes hit 166.34% in 2024, while the deepest fall reached 532.26% in 2024.
  • Year by year, Deferred Taxes stood at $1.2 million in 2021, then plummeted by 116.25% to -$202000.0 in 2022, then surged by 46.53% to -$108000.0 in 2023, then dropped by 24.07% to -$134000.0 in 2024.
  • Business Quant data shows Deferred Taxes for PRME at -$134000.0 in Q2 2024, $134000.0 in Q1 2024, and -$108000.0 in Q3 2023.